References
- MacdougallICNovel erythropoiesis-stimulating agents: a new era in anemia managementClin J Am Soc Nephrol2008320020718077782
- AaproMSAnemia management with erythropoiesis-stimulating agents: a risk-benefit updateOncologist200813Suppl 313
- StramerSLCurrent risks of transfusion-transmitted agents: a reviewArch Pathol Lab Med200713170270717488155
- BernardACDavenportDLChangPKVaughanTBZwischenbergerJBIntraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patientsJ Am Coll Surg200920893193719476865
- LudwigHVan BelleSBarrett-LeePThe European Cancer Anemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsEur J Cancer2004402293230615454256
- CellaDKallichJMcDermottAXuXThe longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trialsAnn Oncol20041597998615151958
- CaroJJSalasMWardAGossGAnemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative reviewCancer2001912214222111413508
- MassaEMadedduCLussoMRGramignanoGMantovaniGEvaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapyCrit Rev Oncol Hematol20065717518216213740
- BrinksVHaweABasmelehAHQuality of original and biosimilar epoetin productsPharm Res20112838639320886265
- European Generic Medicines AssociationBiosimilars Handbook2nd edLondonSage2011
- European Medicines AgencyGuideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-clinical and Clinical IssuesLondonEMA2009
- MichalletMLuporsiESoubeyranPBiosimilars in the management of anemia secondary to chemotherapy in haematology and oncology: results of the ORHEO observational studyBMC Cancer20141450351225011615
- GroopmanJEItriLMChemotherapy-induced anemia in adults: incidence and treatmentJ Nat Cancer Inst1999911616163410511589
- OkenMMCreechRHTormeyDCToxicity and response criteria of the Eastern Cooperative Oncology GroupAm J Clin Oncol198256496557165009
- Janssen-CilagEprex intravenous and subcutaneous injection2014 Available from: http://www.janssen.com.au/files/Products/Eprex_PI.pdfAccessed September 3, 2016
- Cancer Research UKCancer incidence by age2014 Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age#heading-EightAccessed December 19, 2015
- CastelliRDeliliersGLColomboRMoreoGGallipoliPPantaleoGBiosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain functionAnn Hematol2014931523152924711171
- BrodszkyVBajiPBaloghOPentekMBudget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countriesEur J Health Econ201415Suppl 1S65S7124832837
- AaproMCornesPSunDAbrahamIComparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancerTher Adv Med Oncol201249510522590483
- TzekovaVMihaylovGElezovicIKoytchevRTherapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anemiaCurr Med Res Opin2009251689169719505200